Brás Cubas, a sepse e as evidências: reflexões sobre a surviving sepsis campaign

Salluh, Jorge I.; Bozza, Fernando A.; Soares, Márcio; Terzi, Renato Giuseppe Giovanni

doi:10.1590/s0103-507x2006000400002

Cited by 2 publications

(1 citation statement)

References 1 publication

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rush to transfer evidences still being gathered, for recommendation and treatment guidelines of patients with severe sepsis, is a matter of concern that has been subject of intense debate [35][36][37][38] . In the light of the current evidence, the use of DrotAA must be reconsidered until new clinical trials contribute with additional information on the effi cacy, safety and identifi cation of subgroups of patients with severe sepsis that may possibly benefi t from use of this drug.…”

Section: Discussionmentioning

confidence: 99%

O uso da drotrecogina alfa ativada na prática clínica e as atuais evidências

Soares¹,

Machado²,

Torres³

et al. 2008

Rev. bras. ter. intensiva

View full text Add to dashboard Cite

SUMMARY BACKGROUND AND OBJECTIVES:The debate on effi cacy and patient safety related to the use of drotrecogin alfa (DrotAA) is timely, principally due to the negative results observed in clinical studies performed after the PROWESS study, and the economic costrelated impact of the drug on the healthcare system. The aim of this study was to review the main studies on the use of DrotAA in patients with severe sepsis.

show abstract

Section: Discussionmentioning

confidence: 99%

O uso da drotrecogina alfa ativada na prática clínica e as atuais evidências

Soares¹,

Machado²,

Torres³

et al. 2008

Rev. bras. ter. intensiva

View full text Add to dashboard Cite

show abstract

Surviving Sepsis Campaign

Salluh¹,

Bozza

2008

Shock

View full text Add to dashboard Cite

In 2002, the declaration of Barcelona launched a worldwide campaign that proposed to decrease in sepsis-related mortality by the introduction of evidence-based medicine into the management of sepsis. This paved the way for the publication of a wide selection of recommendations entitled the Surviving Sepsis Campaign (SSC) Guidelines. Whereas most of the medical community received the guidelines with enthusiasm, dissonant voices were made public just after its publication, and in recent years, the SSC guidelines were a source of intense debate, resulting in a recent revision of the guidelines. In the midst of a large controversy, it is evident that a critical reappraisal of the SSC guidelines is timely. In our opinion, whereas many relevant aspects of the SSC guidelines have been discussed, there are three major limitations that deserve a closer look, and they are sepsis as a public health issue, the weight of the evidence behind the recommendations, and the absence of recommendations related to the prevention of sepsis. In conclusion, although we recognize that the SSC is a valuable initiative, many of its present aspects must be revised to provide a clear message for clinicians taking care of sepsis patients at bedside. New guidelines should be based on solid evidence, have no interference from the pharmaceutical or medical equipment industry, and should have a stronger preventive and public health approach.

show abstract

Brás Cubas, a sepse e as evidências: reflexões sobre a surviving sepsis campaign

Cited by 2 publications

References 1 publication

O uso da drotrecogina alfa ativada na prática clínica e as atuais evidências

O uso da drotrecogina alfa ativada na prática clínica e as atuais evidências

Surviving Sepsis Campaign

Contact Info

Product

Resources

About